WO2002070510A2 - Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften - Google Patents
Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften Download PDFInfo
- Publication number
- WO2002070510A2 WO2002070510A2 PCT/EP2002/001891 EP0201891W WO02070510A2 WO 2002070510 A2 WO2002070510 A2 WO 2002070510A2 EP 0201891 W EP0201891 W EP 0201891W WO 02070510 A2 WO02070510 A2 WO 02070510A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- chain
- straight
- branched
- substituted
- Prior art date
Links
- 0 *[n]1nccc1 Chemical compound *[n]1nccc1 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N c1cncnc1 Chemical compound c1cncnc1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N c1cnncc1 Chemical compound c1cnncc1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N c1nccnc1 Chemical compound c1nccnc1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 3
- UONSDUXTIAFYDD-UHFFFAOYSA-N N#CCc1cc(CCCC2)c2cc1OCc(cc1)ccc1Br Chemical compound N#CCc1cc(CCCC2)c2cc1OCc(cc1)ccc1Br UONSDUXTIAFYDD-UHFFFAOYSA-N 0.000 description 1
- BENKDPHBHMSIFD-UHFFFAOYSA-N NCCc(cc(CCCC1)c1c1)c1OCc(cc1)ccc1Br Chemical compound NCCc(cc(CCCC1)c1c1)c1OCc(cc1)ccc1Br BENKDPHBHMSIFD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the present invention relates to new chemical compounds which also stimulate soluble guanylate cyclase via a novel mode of action which does not involve the heme group of the enzyme, their production and their use as medicaments, in particular as medicaments for the treatment of cardiovascular diseases.
- Cyclic guanosine monophosphate is one of the most important cellular transmission systems in mammalian cells. Together with nitrogen monoxide (NO), which is released from the endothelium and transmits hormone-like and mechanical signals, it forms the NO / cGMP system.
- NO nitrogen monoxide
- the guanylate cyclases catalyze the biosynthesis of cGMP from guanosine triposphate (GTP).
- GTP guanosine triposphate
- the previously known representatives of this family can be divided into two groups according to structural features and the type of ligand: the particulate guanylate cyclases that can be stimulated by natriuretic peptides and the soluble guanylate cyclases that can be stimulated by NO.
- the soluble guanylate cyclases consist of two subunits and most likely contain one heme per heterodimer, which is part of the regulatory center. This is of central importance for the activation mechanism. NO can bind to the iron atom of the heme and thus significantly increase the activity of the enzyme. Hem-free preparations, on the other hand, cannot be stimulated by NO. CO is also able to attack the central iron atom of the heme, whereby the stimulation by CO is significantly less than that by NO.
- guanylate cyclase plays a decisive role in different physiological processes, in particular in the relaxation and proliferation of smooth muscle cells, platelet aggregation and adhesion and neuronal signal transmission as well as in diseases , which are based on a disturbance of the above-mentioned processes.
- the NO / cGMP system can be suppressed, which leads to Examples include high blood pressure, platelet activation, increased cell proliferation, endothelial dysfunction, atherosclerosis, angina pectoris, heart failure, thrombosis, stroke and myocardial infarction.
- a NO-independent treatment option for such diseases aimed at influencing the cGMP signal path in organisms is a promising approach due to the expected high efficiency and few side effects.
- the previously known stimulators of soluble guanylate cyclase stimulate the enzyme either directly via the heme group (carbon monoxide, nitrogen monoxide or diphenyliodonium hexafluorophosphate) by interaction with the iron center of the heme group and a resulting conformational change that leads to an increase in enzyme activity (Gerzer et al., FEBS Lett. 132 (1981), 71), or via a heme-dependent mechanism that is independent of NO, but too potentiates the stimulating effect of NO or CO (e.g. YC-1, Hoenicka et al., J. Mol. Med. (1999) 14; or that in WO 98/16223, WO 98/16507 and WO 98/23619 described pyrazole derivatives).
- NO or CO e.g. YC-1, Hoenicka et al., J. Mol. Med. (1999) 14; or that in WO 98/16223, WO 98/
- Fatty acids such as B. arachidonic acid, prostaglandin endoperoxides and fatty acid hydroperoxides on the soluble guanylate cyclase could not be confirmed (see e.g. Hoenicka et al., J. Mol. Med. 77 (1999), 14).
- the enzyme still shows a detectable catalytic basal activity, i.e. cGMP is still formed.
- the remaining catalytic basal activity of the heme-free enzyme cannot be stimulated by any of the known stimulators mentioned above.
- protoporphyrin IX A stimulation of heme-free soluble guanylate cyclase by protoporphyrin IX has been described (Ignarro et al., Adv. Pharmacol. 26 (1994), 35).
- protoporphyrin IX can be regarded as facial expressions for the NO-heme adduct, which is why the addition of protoporphyrin IX to the soluble guanylate cyclase should lead to the formation of a structure of the enzyme corresponding to the soluble guanylate cyclase which is stimulated by NO. This is also through the
- the compounds according to the invention are able to stimulate both the heme-containing and the heme-free form of the soluble guanylate cyclase.
- the stimulation of the enzyme with these new stimulators is via a heme-independent path, which is also demonstrated by the fact that the new stimulators on the heme-containing enzyme on the one hand show no synergistic effect with NO and on the other hand the effect of these new stimulators is not affected by Hem-dependent inhibitor of soluble guanylate cyclase, lH-l, 2,4-oxadiazol- (4,3a) -quinoxalin-l-one (ODQ).
- EP-A-0 345 068 describes, inter alia, the aminoalkanecarboxylic acid (1) as an intermediate in the synthesis of GABA antagonists:
- WO 93/00359 describes the aminoalkanecarboxylic acid (2) as an intermediate in peptide synthesis and its use as an active ingredient for treating diseases of the central nervous system:
- Row S, N and / or O is fused, or a partially unsaturated or aromatic heterocycle having 1 to 9 carbon atoms and up to 3
- V is absent, O, NR 4 , NR 4 CONR 4 , NR 4 CO, NR 4 SO 2 , COO, CONR 4 or S (O) 0 ,
- o 0, 1 or 2
- Q is missing, straight chain or branched alkylene, straight chain or branched
- Means alkenediyl or straight-chain or branched alkynediyl each having up to 12 carbon atoms, each of which has one or more groups from O, S (O) p , NR 5 , CO, NR 5 SO 2 or CONR 5 can contain, and can be substituted one or more times by halogen, hydroxy or alkoxy with up to 4 carbon atoms, optionally any two atoms of the above chain to form a three- to eight-membered ring can be connected to one another,
- R 5 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, which can be substituted by halogen or alkoxy having up to 4 carbon atoms,
- R 6 is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, straight-chain or branched haloalkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 7 independently of any further radical R 7 which may be present, denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 8 , R 9 , R 11 and R 12 independently of one another are hydrogen, straight-chain or branched alkyl, straight-chain or branched alkenyl having up to 8 carbon atoms, aryl having 6 to 10 carbon atoms, an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O, arylalkyl with 8 to 18
- R denotes straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn can be substituted one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms,
- R 10 is hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to 12 carbon atoms, aryl having 6 to 10 carbon atoms, an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and or denotes O or cycloalkyl having 3 to 8 carbon atoms, which may optionally further be substituted by halogen, hydroxy, CN, NO 2 , NH 2 , NHCOR 7 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms;
- aryl with 6 to 10 carbon atoms, a saturated carbocycle with 6 to 10 carbon atoms, an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O can be substituted, which can also be bonded via N, which is directly or via a group from O, S, SO, SO 2 , NR 7 , SO 2 NR 7 , CON, straight-chain or branched alkylene, straight-chain or branched alkenediyl , straight-chain or branched alkyloxy, straight-chain or branched oxyalkyloxy, straight-chain or branched sulfonylalkyl, straight-chain or branched thioalkyl, each with up to 8
- Carbon atoms can be bonded and one to three times by straight-chain or branched alkyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched haloalkyl, straight-chain or branched haloalkoxy, carbonylalkyl or straight-chain or branched alkenyl, each with up to 6 Carbon atoms, halogen, SR 6 , CN, NO 2 , NR 8 R 9 , CONR 15 R 16 or NR 14 COR 17 can be substituted,
- R 14 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 15 , R 16 independently of one another are hydrogen, straight-chain or branched
- R 18 denotes straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn being used one or more times by halogen, hydroxy, CN, NO 2 , NH 2 , NHCOR 7 , alkyl, alkoxy, haloalkyl or Haloalkoxy can be substituted with up to 6 carbon atoms,
- R 17 is hydrogen, straight-chain or branched alkyl with up to 12
- Haloalkyl or haloalkoxy can be substituted with up to 6 carbon atoms
- the cyclic radicals can be fused with an aromatic or saturated carbocycle with 1 to 10 carbon atoms or an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O,
- C 6 - alkoxy, NR 19 R 20 , cycloalkyl with 3 to 8 carbon atoms can carry, straight-chain or branched haloalkyl, straight-chain or branched alkoxy, or alkoxycarbonyl with up to 4 carbon atoms each, CN, NO 2 , NR 19 R 20 , SR 17 , SO 2 R 17 , cycloalkyl with 3 to 8 carbon atoms, haloalkoxy haloalkoxy with up to 6 carbon atoms,
- Cycloalkoxy with up to 14 carbon atoms CONH 2 , CONR 17 R 17 , SO 2 NH 2 , SO 2 NR 17 R 17 , alkoxyalkoxy with up to 12 carbon atoms, NHCOOR 17 , NHCOR 17 , NHSO 2 R 17 , NHCONH 2 , OCONR 17 R 17 , OSO 2 R 17 , C 2 -i 2 -alkenyl or C ⁇ .i 2 -alkynyl means
- R 19 and R 20 independently of one another are hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, m represents an integer from 1 to 4,
- W denotes straight-chain or branched alkylene with up to 6 carbon atoms or straight-chain or branched alkenediyl with up to 6 carbon atoms, each of which can contain a group from O, S (O) q , NR 21 , CO or CONR 21 , or CO, NHCO or OCO means
- q 0, 1 or 2
- R 21 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- U denotes straight-chain or branched alkyl having up to 4 carbon atoms
- A is aryl with 6 to 10 carbon atoms or an aromatic heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O, which may be one to three times by halogen, straight-chain or branched alkyl, straight-chain or branched Haloalkyl, straight-chain or branched alkoxy, haloalkoxy or alkoxycarbonyl with up to 4 carbon atoms, CN, NO 2 or NR 22 R 23 can be substituted, in which
- R and R each independently represent hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, carbonylalkyl or sulfonylalkyl.
- R 2 means tetrazolyl, COOR 24 or CONR 25 R 26 ,
- R 24 is hydrogen, alkyl of 1 to 8 carbon atoms or cycloalkyl of 3 to 8 carbon atoms
- R 25 and R 26 each independently represent hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or a radical of the formula SO 2 R 27 , or R 25 and R 26 together represent a five- or six-membered ring form, which can contain N or O,
- R 27 denotes straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn being one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6
- X denotes straight-chain or branched alkylene with up to 12 carbon atoms or straight-chain or branched alkenediyl with up to 12 carbon atoms, each of one to three groups from O, S (O) r , NR 28 , CO or
- CONR 29 may contain aryl or aryloxy having 6 to 10 carbon atoms, the aryl radical in turn being able to be substituted one or more times by halogen, CN, NO, alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms, optionally two random atoms of the above chains are connected to one another by an alkyl chain to form a three- to eight-membered ring, embedded image in which
- r 0, 1 or 2
- R 28 represents hydrogen, alkyl having 1 to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 29 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- n 1 or 2;
- R 1 means tetrazolyl, COOR 30 or CONR 31 R 32 ,
- R 30 is hydrogen, alkyl of 1 to 8 carbon atoms or cycloalkyl of 3 to 8 carbon atoms
- R 31 and R 32 each independently represent hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or a radical of the formula SO 2 R 33 ,
- R means straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn can be substituted one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms,
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- V is absent, O, NR 4 , NR 4 CONR 4 , NR 4 CO, NR 4 SO 2 , COO, CONR 4 or S (O) 0 ,
- R 4 independently of any further radical R 4 which may be present, denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or arylalkyl having 7 to 18 carbon atoms, the aryl radical can in turn be substituted one or more times by halogen, alkyl, alkoxy having up to 6 carbon atoms,
- Q is absent, straight-chain or branched alkylene, straight-chain or branched alkenediyl or straight-chain or branched alkynediyl each having up to 12 carbon atoms, each of which means one or more groups of O, S (O) p , NR 5 , CO, NR 5 SO 2 or CONR 5 can contain, and can be substituted one or more times by halogen, hydroxy or alkoxy with up to 4 carbon atoms, optionally any two atoms of the above chain can be connected to form a three- to eight-membered ring,
- R 5 is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, which can be substituted by halogen or alkoxy having up to 4 carbon atoms,
- p 0, 1 or 2
- Y is hydrogen, NR 8 R 9 , aryl with 6 to 10 carbon atoms, an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O or straight-chain or branched cycloalkyl with 3 to 8 carbon atoms, which can also be bonded via N, the cyclic radicals in each case one to three times by straight-chain or branched alkyl, straight-chain or branched alkenyl, straight-chain or branched alkynyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched Haloalkyl, straight-chain or branched haloalkoxy each having up to 8 carbon atoms, straight-chain or branched cycloalkyl having 3 to 8 carbon atoms, halogen, hydroxy, CN, SR 6 , NO 2 , NR 8 R 9 , NR 7 COR 10
- NR 7 CONR 7 R 10 or CONR ⁇ R 12 can be substituted, embedded image in which
- R 6 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, straight-chain or branched haloalkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 7 independently of any further radical R 7 which may be present, denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 8 , R 9 , R 11 and R 12 independently of one another are hydrogen, straight-chain or branched alkyl, straight-chain or branched alkenyl with up to
- R 13 denotes straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn being used one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms can be substituted
- R 10 is hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to
- Haloalkyl or haloalkoxy can be substituted with up to 6 carbon atoms
- 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O can be substituted, which can also be bonded via N, which directly or via a group from O, S, SO, SO 2 , NR 7 , SO 2 NR 7 , CONR 7 , straight-chain or branched alkylene, straight-chain or branched alkenediyl, straight-chain or branched alkyloxy, straight-chain or branched oxyalkyloxy, straight-chain or branched sulfonylalkyl, straight-chain or branched thioalkyl each having up to 8 carbon atoms and can be bound up to three times by straight-chain or branched alkyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched
- Haloalkyl, straight-chain or branched haloalkoxy, carbonylalkyl or straight-chain or branched alkenyl having in each case up to 6 carbon atoms, halogen, SR 6, CN, NO 2, NR 8 R 9, CONR l5 R 16 or NR 14 COR 17 may be substituted,
- R 14 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 15 , R 16 independently of one another are hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or a radical of the formula SO 2 R 18 ,
- R 18 denotes straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn being substituted one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms can
- R 17 is hydrogen, straight-chain or branched alkyl with up to 12
- 3 heteroatoms from the series S, N and / or O or cycloalkyl with 3 is up to 8 carbon atoms, which may optionally be further substituted by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms;
- Carbocycle with 1 to 10 carbon atoms or an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O can be fused
- R 3 denotes hydrogen, halogen, straight-chain or branched alkyl, straight-chain or branched haloalkyl or straight-chain or branched alkoxy each having up to 4 carbon atoms,
- n an integer from 1 to 4,
- W denotes straight-chain or branched alkylene or straight-chain or branched alkenediyl each having up to 4 carbon atoms
- A is phenyl or an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O, which may be one to three times by halogen, straight-chain or branched alkyl, straight-chain or branched haloalkyl or straight-chain or branched alkoxy with up to 4 carbon atoms, can be substituted,
- R 2 means COOR 24
- R 24 denotes hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms
- X denotes straight-chain or branched alkylene with up to 8 carbon atoms or straight-chain or branched alkenediyl with up to 8 carbon atoms, each of one to three groups from phenyl, phenyloxy, O, CO
- R 29 denotes hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms,
- n 1 or 2;
- R 1 means COOR 30 ,
- R, 30 is hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms.
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- V is absent, O, S or NR 4 means
- R represents hydrogen or methyl
- cyclic radicals are each one to three times by straight-chain or branched alkyl, straight-chain or branched alkenyl, straight-chain or branched alkynyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched haloalkyl, straight-chain or branched haloalkoxy each having up to 4 carbon atoms, straight-chain or branched cycloalkyl having 3 to 6 carbon atoms, F, CI, Br, I, NO 2 , SR 6 , NR 8 R 9 , NR 7 COR 10 or CONR ⁇ R 12 substituted could be,
- R denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, or straight-chain or branched haloalkyl having up to 4 carbon atoms,
- R 7 denotes hydrogen, or straight-chain or branched alkyl having up to 4 carbon atoms
- R 8 , R 9 , R 11 and R 12 independently of one another are hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl, where the phenyl radical is monosubstituted to triple by F, CI Br, hydroxy, methyl, ethyl, n - Propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, Methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN may be substituted, or two substituents from R 8 and R 9 or R 11 and R 12 may be linked to form a five- or six-membered ring, which can be interrupted by O or N,
- R 10 is hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl, where the phenyl radical is monosubstituted to triple by F, Cl Br, hydroxy, methyl, ethyl, n-propyl, i-propyl, n-butyl, see -Butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN;
- R 14 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 17 is hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to
- Butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN may be substituted;
- R 3 represents hydrogen, methyl or fluorine
- n an integer from 1 to 4,
- W denotes CH 2 , -CH 2 CH 2 -, CH 2 CH 2 CH 2)
- CH CHCH 2 ,
- A is phenyl, pyridyl, thienyl or thiazolyl, which is optionally one to three times by methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, CF 3 , methoxy, Ethoxy, F, CI, Br can be substituted,
- R 2 means COOR 24
- R 24 is hydrogen or straight-chain or branched alkyl with up to 4
- X denotes straight-chain or branched alkylene with up to 8 carbon atoms or straight-chain or branched alkenediyl with up to 8 carbon atoms, each of which may contain one to three groups from phenyl, phenyloxy, O, CO or CONR 30 ,
- R 30 denotes hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms
- n 1 or 2;
- R 1 means COOR 35 ,
- R 35 is hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms.
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- the cyclic radicals in each case one to three times by straight-chain or branched alkyl, straight-chain or branched alkenyl, straight-chain or branched alkynyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched haloalkyl, straight-chain or branched haloalkoxy with in each case up to 4 carbon atoms, straight-chain or branched cycloalkyl with 3 to 6 carbon atoms, F, CI, Br, I, NO 2 , SR 6 , NR 8 R 9 , NR 7 COR 10 or CONR n R 12 can be substituted, embedded image in which
- R 6 denotes hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or straight-chain or branched haloalkyl having up to 4 carbon atoms,
- R 7 denotes hydrogen, or straight-chain or branched alkyl having up to 4 carbon atoms
- R 8 , R 9 , R 11 and R 12 independently of one another are hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl, where the phenyl radical is monosubstituted to triple by F, CI Br, hydroxy, methyl, ethyl, n - Propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl,
- Methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN may be substituted, or two substituents from R 8 and R 9 or R 11 and R 12 may be linked to form a five- or six-membered ring, which can be interrupted by O or N,
- R 10 is hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl, where the phenyl radical is monosubstituted to triple by F, Cl Br, hydroxy, methyl, ethyl, n-propyl, i-propyl, n-butyl, see -Butyl, i-butyl, t-butyl,
- Methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN may be substituted;
- R 14 denotes hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, and
- R 17 is hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms, straight-chain or branched alkenyl having up to
- Butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN may be substituted;
- the cyclic radicals can be fused with an aromatic or saturated carbocycle with 1 to 10 carbon atoms or an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O,
- R represents hydrogen, methyl or fluorine
- n an integer from 1 to 2
- W -CH 2 - or -CH 2 CH 2 - means
- A is phenyl, which is optionally one to three times by methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, CF 3 , methoxy, ethoxy, F, CI, Br can be substituted
- R 2 means COOR 24 embedded image in which
- R 24 denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
- R 30 denotes hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms,
- n 1 or 2;
- R 1 means COOR 35 ,
- R 35 is hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms.
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- Y is phenyl which is substituted by a radical selected from the group consisting of 2-phenylethyl, cyclohexyl, 4-chlorophenyl, 4-methoxyphenyl,
- R 3 represents hydrogen, methyl or fluorine
- n an integer from 1 to 2
- A means phenyl
- R 2 means COOH, where R 2 is in the 4-position to the rest U,
- X means (CH 2 )
- R 1 means COOH. Also particularly preferred according to the present invention are compounds in which
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- Q means CH 2 O which is bonded to Z via its carbon atom
- Y is phenyl which is substituted by a radical selected from the group consisting of 2-phenylethyl, cyclohexyl, 4-chlorophenyl, 4-methoxyphenyl, 4-trifmormethylphenyl, 4-cyanophenyl, 4-chlorophenoxy, 4-methoxyphenoxy, 4-trifluoromethylphenoxy, 4-cyanophenoxy, 4-methylphenyl, 4-tert-butylphenyl, 4-carboxyphenyl, 4-fluorophenyl, 3-methoxyphenyl, 2,4-dichlorophenyl is selected,
- R 3 represents hydrogen, methyl or fluorine
- n an integer from 1 to 2
- A means phenyl
- R means COOH, where R2 is arranged in 4 position to the rest U,
- X means (CH 2 ) 4 ,
- R 1 means COOH.
- the compounds of the general formula (I) according to the invention can also be present in the form of their salts. In general, salts with organic or inorganic bases or acids may be mentioned here.
- Physiologically acceptable salts are preferred in the context of the present invention.
- Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids.
- Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids.
- particular preference is given to Salts with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
- Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention which have a free carboxyl group.
- Sodium, potassium, magnesium or calcium salts as well as ammonium salts derived from ammonia, or organic amines such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine.
- the compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
- the invention relates both to the enantiomers or diastereomers and to their respective mixtures.
- the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner, for example by racemate resolution or chromatographic separation.
- Double bonds present in the compounds according to the invention can be in the eis or trans configuration (Z or E form).
- the substituents generally have the following meaning:
- Alkyl generally represents a straight-chain or branched hydrocarbon radical having 1 to 20 carbon atoms.
- Alkylene generally stands for a straight-chain or branched hydrocarbon bridge with 1 to 20 carbon atoms.
- methylene ethylene
- ethylene ethylene
- Alkenyl generally represents a straight-chain or branched hydrocarbon radical having 2 to 20 carbon atoms and one or more, preferably one or two, double bonds. Examples include allyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, isopentenyl, hexenyl, isohexenyl, heptenyl, isoheptenyl, octenyl and isooctenyl.
- Alkynyl generally represents a straight-chain or branched hydrocarbon radical having 2 to 20 carbon atoms and one or more, preferably with one or two triple bonds. Examples include ethynyl, 2-butynyl, 2-pentynyl and 2-hexynyl.
- Alkenediyl generally represents a straight-chain or branched hydrocarbon bridge with 2 to 20 carbon atoms and one or more, preferably with one or two, double bonds.
- Alkenediyl generally represents a straight-chain or branched hydrocarbon bridge with 2 to 20 carbon atoms and one or more, preferably with one or two, double bonds.
- Alkindiyl generally represents a straight-chain or branched hydrocarbon bridge with 2 to 20 carbon atoms and one or more, preferably with one or two triple bonds. Examples include ethyne-1,2-diyl, propyne-1,3-diyl, l-butyne-1,4-diyl, l-butyne-1,3-diyl, 2-butene-1,4-diyl.
- Acyl generally represents straight-chain or branched lower alkyl having 1 to 9 carbon atoms, which is bonded via a carbonyl group. Examples include: acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl and isobutylcarbonyl.
- Alkoxy generally represents a straight-chain or branched hydrocarbon radical having 1 to 14 carbon atoms which is bonded via an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, isopentoxy, hexoxy, isohex oxy, heptoxy, isoheptoxy, octoxy or iso-octoxy.
- alkoxy and “alkyloxy” are used synonymously.
- Alkoxyalkyl generally represents an alkyl radical having up to 8 carbon atoms which is substituted by an alkoxy radical having up to 8 carbon atoms.
- Alkoxycarbonyl can, for example, by the formula
- Alkyl here generally represents a straight-chain or branched hydrocarbon radical having 1 to 13 carbon atoms. Examples include the following alkoxycarbonyl radicals: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl or isobutoxycarbonyl.
- Cycloalkyl generally represents a cyclic hydrocarbon radical having 3 to 8 carbon atoms. Cyclopropyl, cyclopentyl and cyclohexyl are preferred. Examples include cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- Cycloalkoxy in the context of the invention is an alkoxy radical whose hydrocarbon radical is a cycloalkyl radical.
- the cycloalkyl radical generally has up to 8 carbon atoms. Examples include: cyclopropyloxy and cyclohexyloxy.
- the terms "cycloalkoxy” and “cycloalkyloxy” are used synonymously.
- Aryl generally represents an aromatic radical having 6 to 10 carbon atoms.
- Preferred aryl radicals are phenyl and naphthyl.
- Halogen in the context of the invention represents fluorine, chlorine, bromine and iodine.
- heterocycle generally represents a saturated, unsaturated or aromatic 3- to 10-membered, for example 5- or 6-membered, heterocycle which can contain up to 3 heteroatoms from the series S, N and or or and which in the case of a nitrogen atom can also be bound via this.
- heterocycle includes: oxadiazolyl, thiadiazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, piperazinyl,
- Thiazolyl, furyl, oxazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl and tetrahydropyranyl are preferred.
- heteroaryl (or "hetaryl”) stands for an aromatic heterocyclic radical.
- heterocycle structures shown in the present application only one bond to the neighboring group is indicated, for example in the heterocycle structures which are suitable for Y, the bond to the unit Q. Independently of this, however, these heterocycle structures can carry further substituents as indicated.
- the present invention further relates to a process for the preparation of the compounds of the formula (I), characterized in that
- E either represents a leaving group which is substituted in the presence of a base or is an optionally activated hydroxy function
- E either represents a leaving group which is substituted in the presence of a base or is an optionally activated hydroxy function
- E either represents a leaving group which is substituted in the presence of a base or is an optionally activated hydroxy function
- Va stands for O or S
- E either represents a leaving group which is substituted in the presence of a base or is an optionally activated hydroxy function:
- R ⁇ and R 2 b each independently represent CN or COO Alk, where Alk represents a straight-chain or branched alkyl radical having up to 6 carbon atoms,
- M represents an aryl or heteroaryl radical, a straight-chain or branched alkyl, alkenyl or alkynyl radical or cycloalkyl radical or an arylalkyl, an arylalkenyl or an arylalkynyl radical,
- Ar represents an aryl or heteroaryl radical
- R t-Bu
- the compounds of the formula (I) can also be prepared on a solid phase, such as a polystyrene resin, particularly preferably a commercially available Wang polystyrene resin.
- the resin is initially dissolved in a swollen like dimethylformamide (DMF).
- the corresponding carboxylic acid serving as the starting compound is then bound to the resin by standard methods.
- the carboxylic acid can be bound to the resin in the presence of a base such as pyridine or 4-dimethylaminopyridine (DMAP) and a reagent which activates the carboxyl unit, such as an acid halide, for example dichlorobenzoyl chloride, in a solvent such as dimethylformamide (DMF).
- a base such as pyridine or 4-dimethylaminopyridine (DMAP)
- DMAP 4-dimethylaminopyridine
- a reagent which activates the carboxyl unit such as an acid halide, for example dichlorobenzoyl chloride
- reaction mixture is left to stir for at least 2 hours, preferably 12 hours, particularly preferably about 24 hours, at room temperature and normal pressure, the carboxylic acid being used in excess, preferably in a two to three-fold excess, with respect to the loading of the solid phase.
- the carboxylic acid bound to the resin can be derivatized without having to be separated from the resin beforehand.
- a corresponding 4-aminobenzoic acid or 4-formylbenzoic acid derivative can be attached to the resin, then via successive reductive amination reactions, as described below for the preparation of the compounds of the formula (II), (IV) and (VI) a compound of the formula (VUI) are reacted, which can then be converted into the target compounds on the solid phase analogously to process [D].
- the resin is split off after the desired structure of the target compound on the solid phase in a conventional manner in an acidic environment.
- the product separated from the resin can, after removal of any solvents which may be present, be purified by known purification processes, such as, for example, chromatographic processes.
- purification processes such as, for example, chromatographic processes.
- Preferred solvents for the processes according to the invention are conventional organic solvents which do not change under the reaction conditions or water.
- ethers such as diethyl ether, butyl methyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene or petroleum ether, or amides such as dimethylformamide or hexamethylphosphorium triamide, or 1,3-dimethyl-2-imidazole are preferably used for the process according to the invention -on, 1, 3-dimethyl-tetrahydro- pyrimidin-2-one, acetonitrile, ethyl acetate or dimethyl sulfoxide can be used. It is of course also possible to use mixtures of the abovementioned solvents.
- the bases preferred for the processes according to the invention comprise basic compounds conventionally used for basic reactions.
- Alkali metal hydrides such as sodium hydride or potassium hydride, or alkali metal alcoholates such as sodium methoxide, sodium ethanolate, potassium methoxide, potassium ethanolate or potassium t-butoxide, or carbonates such as sodium carbonate, cesium carbonate or potassium carbonate or amides such as sodium amide or lithium diisopropylamide, or organolith such as phenyllithium, butyllithium or methyl lithium or sodium hexamethyldisilazane can be used.
- Processes A to C according to the invention can preferably be carried out in acetonitrile in each case by reaction of the compounds (II) and (UT), (TV) and (V) or (VI) and (VII) in the presence of a base such as sodium carbonate, Et 3 N, DABCO , K 2 CO 3 , KOH, NaOH or NaH can be carried out.
- the reaction can generally be carried out in a temperature range from -20 ° C. to + 90 ° C., preferably from 0 ° C. to + 70 ° C.
- the reaction can be carried out at normal pressure, elevated or reduced pressure (for example in a range from 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.
- the following leaving groups E are, for example: halogen, tosylate, mesylate, or a hydroxyl function activated by reagents such as diisopropylazodicarboxylate / PPh 3 (Mitsonobu reaction).
- Process D according to the invention can preferably be carried out in acetonitrile by reaction of the compounds (VTH) and (IX) in the presence of a base such as sodium carbonate, potassium carbonate, Et 3 N, DABCO, K 2 CO 3 , KOH, NaOH or NaH.
- the reaction can generally be carried out in a temperature range from -20 ° C. to + 90 ° C., preferably from 0 ° C. to + 90 ° C.
- the reaction can be carried out at normal pressure, elevated or reduced pressure (for example in a range from 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.
- a compound of the formula (I) is prepared by nucleophilic substitution of a leaving group E in the compound of the formula (LX) by the hydroxyl or thiol function of the compound of the formula (Vi ⁇ ).
- the following leaving groups E are, for example: halogen, tosylate, mesylate, or a hydroxyl function activated by reagents such as diisopropylazodicarboxylate / PPh 3 (Mitsonobu reaction).
- a compound of the formula (I) in which R 1 and R 2 each represent a free carboxyl function is obtained by converting ester and / or nitrile functions of the compound (X) into the corresponding free carboxyl functions.
- This reaction can be carried out, for example, by adding aqueous solutions of strong acids such as HC1 or H 2 SO 4 , or strong bases such as NaOH, KOH or LiOH.
- the reaction can be carried out in one of the abovementioned organic solvents, in water or in mixtures of organic solvents or in mixtures of organic solvents with water. According to the invention, for example, is preferred
- the reaction can generally be carried out in a temperature range from -20 ° C. to + 90 ° C., preferably from 0 ° C. to + 90 ° C.
- the reaction can be carried out at normal pressure, elevated or reduced pressure (for example in a range from 0.5 to 5 bar). In general, the reaction
- a compound of the formula (I) is reacted by reacting a compound of the formula (XI) which contains a substitutable group L with a compound of the group (XII) in the presence of a palladium compound and, if appropriate, a reducing agent and other additives represented in basic medium.
- the reaction formally represents a reductive coupling of the compounds of the formulas (XI) and (XII), as described, for example, in LS Hegedus, Organometallics in Synthesis, M. Schlosser, Ed., Wiley & Sons, 1994.
- substitutable group L in the compounds of the formula (XI) for example a halogen radical such as Br or I or a conventional leaving group such as a triflate radical can be used.
- a palladium (II) compound such as Cl 2 Pd (PPh 3 ) 2 or Pd (OAc) 2 or a palladium (O) compound such as Pd (PPh 3 ) 4 or Pd 2 (dba) 3 can be used as the palladium compound become.
- a reducing agent such as triphenylphosphine or other additives such as Cu (I) Br, NBu 4 NCl, LiCl or Ag 3 PO 4 can also be added to the reaction mixture (cf. T Jeffery, Tetrahedron lett. 1985, 26, 2667-2670; T. Jeffery, J. Chem. Soc, Chem. Commun. 1984, 1287-1289; S. Bräse, A. deMejiere in "Metal-catalyzed cross-coupling reactions", Ed. F. Diederich, PJ Stang , Wiley-VCH,
- the reaction is carried out in the presence of a conventional base such as Na 2 CO 3 , NaOH or triethylamine.
- Suitable solvents are the organic solvents mentioned above, ethers such as dimethoxyethane being particularly preferred.
- the reaction can generally be in one Temperature range from -20 ° C to + 90 ° C, preferably from 0 ° C to + 90 ° C.
- the reaction can be carried out at normal pressure, elevated or reduced pressure (for example in a range from 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.
- the first step of process G thus proceeds analogously to process D, with compounds of the formula (XIH) being reacted with the alcohols or thiols of the formula (XIII) here instead of the compounds of the formula (IX).
- the unsaturated compounds of the formula (XIV) are thus obtained, which can be converted into the compounds of the formula (I) by conventional hydrogenation processes.
- Process G can be carried out in one of the above-mentioned organic solvents. Ethyl acetate is preferred.
- the reaction can generally be carried out in a temperature range from -20 ° C. to + 90 ° C., preferably from 0 ° C. to + 90 ° C.
- the reaction can be carried out at normal pressure, elevated or reduced pressure (for example in a range from 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.
- the new compounds of the formula II, IV and VI can be obtained in a generally known manner by the following methods: by reaction of amines of the formulas (XV), (XVI) and (XV ⁇ )
- radicals R 2 , R 3 , m, V, Q, U, W, X, Y and A have the meanings given above;
- Ua, Wa and Xa have the meaning of U, W and X, but are shortened by one carbon unit, and
- T represents hydrogen or a -CC alkyl function, which can also be linked to Ua or Xa to form a cycle, and the other radicals are as defined above,
- Va O or S
- the other residues are as defined above.
- (Ilb) is obtained, for example, by first reacting (XVa) with (XVIII) to form a Schiff base and then reducing it with common reducing agents, such as NaBH, H 2 / Pd / C etc., or directly under the conditions of a reductive one
- a compound of formula (XXIII) can be obtained from the compound of formula (IIc) thus obtained by protecting the amino function (see also T.W. Greene, P.G.M.
- an N-protecting group as in (XXII) can be introduced and removed using standard methods (cf. TW Greene, PGM Wuts, Protective Groups in Organic Synthesis, second edition, New York, 1991).
- the protective group can be introduced by reacting the amine with tert-butyl pyrrocarbonate in polar or non-polar solvents at 0 ° C to 25 ° C.
- the protecting group can be split off to (Ila) using numerous acids, such as, for example, HC1, H 2 SO 4 or CF 3 COOH, at from 0 ° to 25 ° C. (cf. literature cited above).
- 4-chloromethylbiphenyl compounds which carry a further substituent in the 4'-position can be obtained by coupling 4- (B (OH) 2 - Ph-CHO with the corresponding bromophenyl compounds substituted in the 4-position in the presence of palladium catalysts, such as for example Pd (PPh 3 ) or PdCl 2 (PPh3) 2 and sodium carbonate to the corresponding biphenyl Compounds and subsequent reduction to alcohol with NaBH 4 and conversion to the corresponding chloride with SOCl 2 are prepared.
- palladium catalysts such as for example Pd (PPh 3 ) or PdCl 2 (PPh3) 2
- the compounds can also be prepared by generally known methods, e.g. by reacting an alcohol with a chlorination reagent, e.g. Thionyl chloride or sulfuryl chloride can be produced (see e.g. J. March, Advanced Organic Chemistry, fourth edition, Wiley, 1992, page 1274 or the literature cited therein).
- a chlorination reagent e.g. Thionyl chloride or sulfuryl chloride
- Amines of the formula (XV) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature (cf., for example, Tetrahedron 1997, 53, 2075; J. Med. Chem. 1984, 27, 1321; WO97 / 29079; J. Org. Chem. 1982, 47, 5396).
- these compounds can be selected from the corresponding halide compounds and in particular chloride compounds in which a W'-Hal group is used instead of the W-NH 2 radicals of the compounds of the formula (XV), where W 'is a radical W shortened by one C atom, by substitution of the halide residue by a cyano group to obtain the corresponding nitrile compounds and reduction of the nitrile group or by reaction of corresponding aldehyde compounds in which instead of the residues W-NH 2 of the compounds of the formula (XV) there is a group W'-CHO, where W represents a radical W shortened by one carbon atom, can be obtained with nitromethane and subsequent reduction.
- W'-Hal group is used instead of the W-NH 2 radicals of the compounds of the formula (XV)
- a few exemplary synthetic routes for the amines of the formula (XV) are listed below, the reagents indicated generally representing only one of several possibilities.
- a reduction reaction from aldehyde to alcohol groups, substitution of alcohol groups by halogen groups, substitution of halogen functions by nitrile groups, or reductions of nitrile groups to corresponding amino groups can be carried out with all reactants conventionally used for such reactions (cf. e.g. the corresponding chapter in March, Advanced Organic Chemistry, Wiley, 3 , ed., 1985).
- the radicals given have the same meaning as defined above.
- This synthetic route can be used, for example, starting from commercially available or known hydroxycarboxylic acids:
- the corresponding hydroxycarboxylic acids or hydroxycarnonic esters can also be used instead of the hydroxyaldehydes become.
- the conversion of the primary hydroxyl group into the nitrile group can also be carried out via the corresponding bromide, mesylate, tosylate or acetate instead of via the corresponding halide.
- This process can be used, for example, starting from 2-hydroxynaphth-1-aldehyde, 1-hydroxymethyl-2-methoxynaphthalene or one of the following commercially available or literature-known hydroxyaldehydes:
- the 2-cyanomethyl-3-hydroxypyridine is also according to Desideri et al, J. Heterocycl.
- Amines of the formula (XVI) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature (cf., for example, J. Am. Chem. Soc. 1982, 104, 6801; Chem. Lett. 1984, 1733; J. Med Chem. 1998, 41, 5219; DE-2059922).
- Amines of the formula (XVII) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature (see, for example, J. Org. Chem. 1968, 33, 1581; Bull. Chem. Soc. Jpn. 1973, 46, 968 ; J. Am. Chem. Soc. 1958, 80, 1510; J. Org. Chem. 1961, 26, 2507; Synth. Commun. 1989, 19, 1787).
- Amines of the formulas (XV), (XVI) and (XVII) can also be according to generally known
- Carbonyl compounds of the formula (XVIII) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature (see e.g. J. Med. Chem. 1989, 32, 1277; Chem. Ber. 1938, 71, 335; Bull. Soc. Chim. Fr. 1996, 123, 679).
- Carbonyl compounds of the formula (XIX) are commercially available, known from the literature, or can be synthesized in analogy to processes known from the literature,
- Carbonyl compounds of the formula (XX) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature
- Carbonyl compounds of the formulas (XVIII), (XIX) and (XX) can also be prepared by generally known methods, e.g. by oxidation of alcohols, the reduction of acid chlorides, or the reduction of nitriles (see e.g. J.
- the compounds according to the invention show an unforeseeable, valuable spectrum of pharmacological activity.
- the compounds according to the invention in particular the compounds of the general formula (I), lead to vascular relaxation, platelet aggregation inhibition and to a reduction in blood pressure and to an increase in the coronary blood flow. These effects are mediated by direct stimulation of soluble guanylate cyclase and an intracellular increase in cGMP.
- cardiovascular diseases such as, for example, for the treatment of high blood pressure and heart failure, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, of arrhythmias, for the treatment of thromboembolic diseases and ischemia such as myocardial infarction, stroke, transistoric and Ischemic attacks, peripheral circulatory disorders, prevention of restenoses such as after thrombolysis therapies, percutaneous transluminal angioplasties (PTA), percutaneous transluminal coronary angioplasties (PTCA), bypass and for the treatment of arteriosclerosis, fibrotic diseases such as liver fibrosis and diseases of the pulmonary fibrosis or pulmonary fibrosis system, for example, of the uterine fibrosis or pulmonary fibrosis system, for example, of the asthma or pulmonary fibrosis system Prostate hypertrophy, erectile dysfunction, female sexual dysfunction and incontinence as well as for the treatment of glaucoma.
- thromboembolic diseases and ischemia such as myocardial infar
- the compounds described in the present invention are also active compounds for combating diseases in the central nervous system which are characterized by disorders of the NO / cGMP system.
- they are suitable for eliminating cognitive deficits, for improving learning and memory and for treating Alzheimer's disease.
- They are also suitable for the treatment of diseases of the central nervous system such as anxiety, tension and depression, central nervous system-related sexual dysfunctions and sleep disorders, as well as for the regulation of pathological disorders in the intake of food, beverages and addictive substances.
- the active ingredients are also suitable for regulating cerebral blood flow and are therefore effective means of combating migraines.
- the compounds according to the invention in particular the compounds of the general formula (I), can likewise be used to combat painful conditions.
- the compounds according to the invention have anti-inflammatory activity and can therefore be used as anti-inflammatory agents.
- Rabbits are anesthetized or killed by intravenous injection of thiopental sodium (approx. 50 mg / kg,) and exsanguinated.
- the saphenous artery is removed and divided into 3 mm wide rings.
- the rings are individually mounted on a triangular pair of hooks made of 0.3 mm special wire (Remanium®) that is open at the end.
- Each ring is placed in 5 ml organ baths with 37 ° C warm, carbogen-gassed Krebs-Henseleit solution of the following composition (mM): NaCl: 119; KC1: 4.8; CaCl 2 x 2 H 2 O: 1; MgSO 4 x 7 H 2 O: 1.4; KH 2 PO 4 : 1.2; NaHCO3: 25; Glucose: 10; Bovine serum albumin: 0.001%.
- the contraction force is recorded with Statham UC2 cells, amplified and digitized via A / D converter (DAS-1802 HC, Keithley Instruments Munich), and recorded in parallel on line recorders. Contractions are induced by adding phenylephrine.
- the substance to be examined is added in increasing doses in each further run and the level of the contraction achieved under the influence of the test substance is compared with the level of the contraction achieved in the last previous run. From this, the concentration is calculated, which is necessary to achieve the contraction achieved in the pre-control Reduce 50% (IC 50 ).
- the standard application volume is 5 ⁇ l.
- the DMSO proportion in the bath solution corresponds to 0.1%.
- Stasch Purified soluble guanylyl cyclase expressed in a baculovirus / Sf9 System: Stimulation by YC-1, nitric oxide, and carbon oxide. J. Mol. Med. 77 (1999): 14-23.
- the heme-free guanylate cyclase was obtained by adding Tween 20 to the sample buffer (0.5% in the final concentration).
- the activation of the sGC by a test substance is given as n-fold stimulation of the basal activity.
- the present invention includes pharmaceutical preparations which, in addition to non-toxic, inert pharmaceutically suitable excipients, include the inventive
- the active ingredient can optionally also be present in microencapsulated form in one or more of the carriers mentioned above.
- the therapeutically active compounds in particular the compounds of the general formula (I), should be present in the pharmaceutical preparations listed above in a concentration of about 0.1 to 99.5, preferably about 0.5 to 95% by weight of the total mixture to be available.
- the pharmaceutical preparations listed above can also contain further active pharmaceutical ingredients.
- the active ingredient (s) according to the invention in total amounts of about 0.5 to about 500, preferably 5 to 100 mg / kg of body weight per 24 hours, optionally in the form multiple doses to achieve the desired results.
- a single dose contains the one or more according to the invention
- Active ingredients preferably in amounts of about 1 to about 80, in particular 3 to 30 mg / kg body weight.
- BABA n-butyl acetate / n-butanol / glacial acetic acid / phosphate buffer pH 6
- the mixture is heated to reflux for five hours. After cooling, it is acidified with dilute hydrochloric acid and briefly heated again (5 minutes). Then it is made alkaline with sodium hydroxide solution and extracted with ether. The organic extract is dried over anhydrous sodium sulfate. After filtering and spinning in, 14.2 g of a yellow waxy solid are obtained, which is only approx.
- the toluene is then removed on a tot evaporator and the residue is taken up in methanol.
- the methanolic solution is mixed with ice cooling with 2.34 g (61.77 mmol) of solid sodium borohydride. After stirring for 30 minutes at room temperature, the mixture is neutralized with 5% sodium dihydrogenphosphate solution, diluted with water and extracted with ether. The organic phase is over
- the crude product obtained is purified by column chromatography (dichloromethane / methanol acetic acid 100: 10: 1.5) and 325 mg (1.01 mmol, 10% yield) of a colorless oil are obtained.
- Solvent B 0.3g HC1 (30%) / ll water gradient: A / B 2/98 to 95/5 within 2.5 min
- UV detector DAD 208-400 nm
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002234645A AU2002234645A1 (en) | 2001-03-07 | 2002-02-22 | Amino dicarboxylic acid derivatives with pharmaceutical properties |
EP02701292A EP1368335A2 (de) | 2001-03-07 | 2002-02-22 | Aminodikarbonsäurederivate mit pharmazeutischen eigenschaften |
CA2439756A CA2439756C (en) | 2001-03-07 | 2002-02-22 | Substituted aminodicarboxylic acid derivatives with pharmaceutical properties |
JP2002569830A JP4535679B2 (ja) | 2001-03-07 | 2002-02-22 | 医薬的特性を有する置換アミノジカルボン酸誘導体 |
US10/469,817 US20040082798A1 (en) | 2001-03-07 | 2002-02-22 | Novel amino dicarboxylic acid derivatives with pharmaceutical properties |
US11/581,261 US7705043B2 (en) | 2001-03-07 | 2006-10-10 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10110750.1 | 2001-03-07 | ||
DE10110750A DE10110750A1 (de) | 2001-03-07 | 2001-03-07 | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10469817 A-371-Of-International | 2002-02-22 | ||
US11/581,261 Continuation US7705043B2 (en) | 2001-03-07 | 2006-10-10 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002070510A2 true WO2002070510A2 (de) | 2002-09-12 |
WO2002070510A3 WO2002070510A3 (de) | 2003-01-30 |
Family
ID=7676478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/001891 WO2002070510A2 (de) | 2001-03-07 | 2002-02-22 | Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften |
Country Status (7)
Country | Link |
---|---|
US (2) | US20040082798A1 (de) |
EP (1) | EP1368335A2 (de) |
JP (1) | JP4535679B2 (de) |
AU (1) | AU2002234645A1 (de) |
CA (1) | CA2439756C (de) |
DE (1) | DE10110750A1 (de) |
WO (1) | WO2002070510A2 (de) |
Cited By (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2006077424A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2007045366A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische verbindungen mit carboxyl-isosteren gruppen und ihre verwendung zur behandlung von herz-kreislauf-erkrankungen |
US7276608B2 (en) | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
WO2007134862A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Ag | Substituierte arylimidaz0l0ne und -triaz0l0ne als inhibitoren der vasopressin-rezeptoren |
US7323475B2 (en) | 2003-06-06 | 2008-01-29 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
DE102007015034A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
DE102007019690A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102007019691A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
DE102007027799A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
DE102007027800A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
DE102007051762A1 (de) | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
DE102007054786A1 (de) | 2007-11-16 | 2009-05-20 | Bayer Healthcare Ag | Trisubstituierte Furopyrimidine und ihre Verwendung |
DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
DE102007061763A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102007061764A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102007061766A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102007061757A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung |
DE102008007400A1 (de) | 2008-02-04 | 2009-08-06 | Bayer Healthcare Ag | Substituierte Furane und ihre Verwendung |
DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
DE102008022521A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
DE102008030207A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung |
DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
US7645881B2 (en) | 2004-07-22 | 2010-01-12 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
DE102008039082A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
DE102008039083A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
US7696223B2 (en) | 2006-04-04 | 2010-04-13 | Fibrogen, Inc. | Pyrrolo- and Thiazolo-pyridine compounds, and methods of use thereof |
DE102008052013A1 (de) | 2008-10-17 | 2010-04-22 | Bayer Schering Pharma Aktiengesellschaft | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102008054205A1 (de) | 2008-10-31 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102008062566A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
DE102009004197A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
WO2010086101A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte dicyanopyridine und deren aminosäureester-prodrugs |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2010105770A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-acetamido-5-aryl-1,2,4-triazolone und deren verwendung |
DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
DE102009016553A1 (de) | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2011023703A1 (de) | 2009-08-27 | 2011-03-03 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclische-substituierte 2-acetamido-5-aryl-1,2,4-triazolone und deren verwendung |
US7928120B2 (en) | 2006-01-27 | 2011-04-19 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
WO2011104322A1 (de) | 2010-02-27 | 2011-09-01 | Bayer Pharma Aktiengesellschaft | Bis-arylverknüpfte aryltriazolone und ihre verwendung |
US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
WO2011161099A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Pharma Aktiengesellschaft | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
WO2012000945A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Pharma Aktiengesellschaft | Substituierte dicyanopyridine und ihre verwendung |
WO2012007539A1 (en) | 2010-07-14 | 2012-01-19 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
US8168821B2 (en) | 2005-10-21 | 2012-05-01 | Bayer Pharma Aktiengesellschaft | Cyclopropylacetic acid derivatives and use thereof |
US8173704B2 (en) | 2005-10-21 | 2012-05-08 | Bayer Pharma Aktiengesellschaft | Difluorophenol derivatives and their use |
US8183271B2 (en) | 2005-10-21 | 2012-05-22 | Bayer Intellectual Property Gmbh | Tetrazole derivatives and their use for the treatment of cardiovascular diseases |
US8309596B2 (en) | 2007-06-28 | 2012-11-13 | Novartis Ag | Kallikrein 7 modulators |
WO2013004607A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
WO2013007563A1 (en) | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
WO2013030802A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
US8404723B2 (en) | 2006-09-22 | 2013-03-26 | Bayer Intellectual Property Gmbh | 3-cyano 5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases |
WO2013105063A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013105058A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013105061A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013105057A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013105066A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Salts of an ip receptor agonist |
WO2013105065A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pah and related disorders |
WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
WO2013167495A1 (de) | 2012-05-09 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Bicyclisch-substituierte uracile und ihre verwendung |
US8609727B2 (en) | 2005-10-21 | 2013-12-17 | Bayer Intellectual Property Gmbh | Dicarboxylic acid derivatives and their use |
WO2014012935A1 (de) | 2012-07-20 | 2014-01-23 | Bayer Pharma Aktiengesellschaft | Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung |
WO2014012934A1 (de) | 2012-07-20 | 2014-01-23 | Bayer Pharma Aktiengesellschaft | Neue 5-aminotetrahydrochinolin-2-carbonsäuren und ihre verwendung |
WO2014125413A1 (en) | 2013-02-13 | 2014-08-21 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
WO2014132220A1 (en) | 2013-03-01 | 2014-09-04 | Novartis Ag | Solid forms of bicyclic heterocyclic derivatives as pdgf receptor mediators |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US8927591B2 (en) | 2008-11-14 | 2015-01-06 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
WO2015036563A1 (de) | 2013-09-16 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten |
WO2015052065A1 (de) | 2013-10-07 | 2015-04-16 | Bayer Pharma Aktiengesellschaft | Cyclische thienouracil-carboxamide und ihre verwendung |
WO2015091415A1 (de) | 2013-12-19 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten |
US9115085B2 (en) | 2012-07-16 | 2015-08-25 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
WO2015150350A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen |
WO2015150362A2 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung |
WO2015162456A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162459A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162461A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2016037954A1 (de) | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung |
US9340511B2 (en) | 2012-07-16 | 2016-05-17 | Fibrogen, Inc. | Process for making isoquinoline compounds |
WO2016113205A1 (de) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pentafluorethylpyrimidinone und ihre verwendung |
US9409892B2 (en) | 2012-03-09 | 2016-08-09 | Fibrogen, Inc. | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors |
WO2016150901A1 (de) | 2015-03-26 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Heterocyclylmethyl-thienouracile als antagonisten des adenosin-a2b-rezeptors |
WO2016177660A1 (en) | 2015-05-06 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
WO2017032673A1 (de) | 2015-08-21 | 2017-03-02 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff |
US9624198B2 (en) | 2013-12-19 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Substituted piperidinyltetrahydroquinolines |
US9624199B2 (en) | 2013-12-19 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Substituted bipiperidinyl derivatives |
US9643928B2 (en) | 2013-01-24 | 2017-05-09 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
WO2017081044A1 (en) | 2015-11-13 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
US9695131B2 (en) | 2013-11-08 | 2017-07-04 | Bayer Pharma Aktiengesellschaft | Substituted uracils as chymase inhibitors |
US9751843B2 (en) | 2013-11-08 | 2017-09-05 | Bayer Pharma Aktiengesellschaft | Substituted uracils and use thereof |
WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
US9765067B2 (en) | 2014-07-02 | 2017-09-19 | Novartis Ag | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators |
US9771352B2 (en) | 2014-11-03 | 2017-09-26 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
WO2017191115A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
WO2017191102A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
WO2017191114A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
WO2017191105A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
WO2017191107A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted phenyltriazole derivatives and uses thereof |
WO2018011017A1 (de) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
WO2018015196A1 (de) | 2016-07-20 | 2018-01-25 | Bayer Aktiengesellschaft | Substituierte diazaheterobicyclische verbindungen und ihre verwendung |
WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
WO2018050510A1 (de) | 2016-09-14 | 2018-03-22 | Bayer Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
WO2018054846A1 (de) | 2016-09-23 | 2018-03-29 | Bayer Aktiengesellschaft | N3-cyclisch substituierte thienouracile und ihre verwendung |
US9944621B2 (en) | 2013-12-19 | 2018-04-17 | Bayer Pharma Aktiengesellschaft | Substituted piperidinyl tetrahydroquinolines |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018069222A1 (en) | 2016-10-14 | 2018-04-19 | Bayer Aktiengesellschaft | Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof |
WO2018073144A1 (en) | 2016-10-20 | 2018-04-26 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
US9957254B2 (en) | 2014-07-02 | 2018-05-01 | Novartis Ag | Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators |
EP3338764A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
EP3338803A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
WO2018114503A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
WO2018114501A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
WO2018148419A1 (en) | 2017-02-08 | 2018-08-16 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US10059707B2 (en) | 2014-08-01 | 2018-08-28 | Bayer Pharma AG | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro- 1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient |
WO2018189012A1 (de) | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituierte n-arylethyl-2-aminochinolin-4-carboxamide und ihre verwendung |
WO2018189011A1 (de) | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung |
US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
WO2018228909A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof as task-1 and task-3 inhibitors |
WO2018228907A1 (de) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen |
US10208018B2 (en) | 2014-07-02 | 2019-02-19 | Novartis Ag | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators |
WO2019081302A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081306A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
WO2019081307A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081303A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081292A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081299A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | AMINE SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019091847A1 (de) | 2017-11-07 | 2019-05-16 | Bayer Aktiengesellschaft | Substituierte 2,4-dihydro-3h-1,2,4-triazol-3-one und ihre verwendung |
EP3498298A1 (de) | 2017-12-15 | 2019-06-19 | Bayer AG | Verwendung von sgc-stimulatoren und sgc-aktivatoren alleine oder in kombination mit pde5-inhibitoren zur behandlung von knochenerkrankungen einschliesslich osteogenesis imperfecta (oi) |
EP3553082A1 (de) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Natriuretische peptidgepfropfte antikörper im gehirn |
EP3553081A1 (de) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Natriuretische peptidgepfropfte antikörper im vorhof |
EP3553079A1 (de) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Mit natriuretischem peptid vom c-typ gepfropfte antikörper |
WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
WO2019219517A1 (en) | 2018-05-17 | 2019-11-21 | Bayer Aktiengesellschaft | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
WO2019219672A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
WO2019223629A1 (zh) | 2018-05-22 | 2019-11-28 | 广东东阳光药业有限公司 | 苯基取代的二氢萘啶类化合物及其用途 |
EP3574905A1 (de) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Verfahren zum identifizieren einer untergruppe von patienten mit dcssc, die von einer behandlung mit sgc-stimulatoren und sgc-aktivatoren in einem höheren grad als eine kontrollgruppe profitiert |
US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
WO2020109109A1 (de) | 2018-11-27 | 2020-06-04 | Bayer Aktiengesellschaft | Verfahren zur herstellung von pharmazeutischen darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
US10722501B2 (en) | 2016-05-09 | 2020-07-28 | Bayer Aktiengesellschaft | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof |
WO2020165031A1 (de) | 2019-02-15 | 2020-08-20 | Bayer Aktiengesellschaft | Substituierte isochinolin-piperidinylmethanon-derivate |
WO2020165010A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
US10759794B2 (en) | 2015-12-10 | 2020-09-01 | Bayer Pharma Aktiengesellschaft | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders |
WO2021078135A1 (zh) | 2019-10-25 | 2021-04-29 | 广东东阳光药业有限公司 | 吡咯酰胺类化合物及其用途 |
WO2021089683A1 (en) | 2019-11-06 | 2021-05-14 | Bayer Aktiengesellschaft | Inhibitors of adrenoreceptor adrac2 |
WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021167458A1 (en) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
WO2021172982A1 (en) | 2020-02-26 | 2021-09-02 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
CN113563250A (zh) * | 2021-07-28 | 2021-10-29 | 南华大学 | 一种苯甲酸色胺衍生物及其制备与应用 |
WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
EP4011873A1 (de) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituierte pyrazolo-piperidin-carbonsäuren |
EP4011874A1 (de) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituierte pyrazolo-piperidin-carbonsäuren |
WO2022122914A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
WO2022122916A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
WO2022122917A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
US11426412B2 (en) | 2017-10-18 | 2022-08-30 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
US11529341B2 (en) | 2018-03-13 | 2022-12-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
DE10109859A1 (de) * | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige Aminodicarbonsäurederivate |
DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10216145A1 (de) * | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
BRPI0512261A (pt) | 2004-06-17 | 2008-02-26 | Wyeth Corp | antagonistas de receptor de hormÈnio liberador de gonadotropina |
US7714130B2 (en) | 2004-06-17 | 2010-05-11 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
EP2532650A3 (de) | 2004-06-24 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulatoren von Transportern der ATP-bindenden Kassette |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
DE102004042607A1 (de) * | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
WO2006032851A1 (en) * | 2004-09-20 | 2006-03-30 | Biolipox Ab | Pyrazole compounds useful in the treatment of inflammation |
WO2006058012A2 (en) * | 2004-11-23 | 2006-06-01 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
BRPI0518096A (pt) | 2004-12-01 | 2008-10-28 | Kalypsys Inc | composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos |
CA2593993C (en) * | 2004-12-30 | 2014-07-29 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
TW200800911A (en) * | 2005-10-20 | 2008-01-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
TW200732320A (en) * | 2005-10-31 | 2007-09-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
EA200801108A1 (ru) * | 2005-10-31 | 2008-10-30 | Биолипокс Аб | Триазолы, пригодные для лечения воспалений |
US20090088463A1 (en) * | 2005-11-01 | 2009-04-02 | Benjamin Pelcman | Pyrazoles Useful in the Treatment of Inflammation |
JP2009521468A (ja) * | 2005-12-24 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Abc輸送体の調節因子としてのキノリン−4−オン誘導体 |
PL3219705T3 (pl) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
US20110159111A1 (en) * | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8435970B2 (en) | 2006-06-29 | 2013-05-07 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea |
BRPI0714629A2 (pt) * | 2006-08-21 | 2013-05-07 | Genentech Inc | composto, composiÇço farmacÊutica, mÉtodo para inibir o crescimento celular, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para trataruma doenÇa auto-imune, lesço àsseo destrutiva, distérbios proliferativos, doenÇas infecciosas, doenÇas virais, doenÇas fibràticas ou doenÇas neurodegenerativas |
BRPI0714635A2 (pt) * | 2006-08-21 | 2013-06-18 | Genentech Inc | compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune |
DE102006042143A1 (de) * | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006056740A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102006056739A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102007035367A1 (de) * | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
JP5432890B2 (ja) | 2008-04-04 | 2014-03-05 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
CA2726020C (en) * | 2008-05-29 | 2016-08-16 | Bayer Schering Pharma Aktiengesellschaft | 2-alkoxy-substituted dicyanopyridines and use thereof |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
US8476442B2 (en) | 2009-03-20 | 2013-07-02 | Vertex Pharmaceutical Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
MA34249B1 (fr) | 2010-05-26 | 2013-05-02 | Bayer Ip Gmbh | Utilisation de stimulateurs de la sgc, d'activateurs de la sgc, seuls et en association avec des inhibiteurs de la pde5 en vue du traitement de la sclérodermie systémique |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
RU2692779C2 (ru) | 2012-02-27 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
WO2015011086A1 (en) | 2013-07-25 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
CN105658621B (zh) * | 2013-10-15 | 2018-05-29 | 东亚荣养株式会社 | 4-氨甲基苯甲酸衍生物 |
CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
AU2020365108A1 (en) | 2019-10-18 | 2022-04-21 | Atengen, Inc. | 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000051971A1 (en) * | 1999-03-01 | 2000-09-08 | Pfizer Products Inc. | Oxamic acids and derivatives as thyroid receptor ligands |
FR2794742A1 (fr) * | 1999-06-11 | 2000-12-15 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
AU1619397A (en) * | 1996-02-07 | 1997-08-28 | Banyu Pharmaceutical Co., Ltd. | N,n-disubstituted amic acid derivatives |
-
2001
- 2001-03-07 DE DE10110750A patent/DE10110750A1/de not_active Withdrawn
-
2002
- 2002-02-22 CA CA2439756A patent/CA2439756C/en not_active Expired - Fee Related
- 2002-02-22 JP JP2002569830A patent/JP4535679B2/ja not_active Expired - Fee Related
- 2002-02-22 WO PCT/EP2002/001891 patent/WO2002070510A2/de active Application Filing
- 2002-02-22 AU AU2002234645A patent/AU2002234645A1/en not_active Abandoned
- 2002-02-22 US US10/469,817 patent/US20040082798A1/en not_active Abandoned
- 2002-02-22 EP EP02701292A patent/EP1368335A2/de not_active Withdrawn
-
2006
- 2006-10-10 US US11/581,261 patent/US7705043B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000051971A1 (en) * | 1999-03-01 | 2000-09-08 | Pfizer Products Inc. | Oxamic acids and derivatives as thyroid receptor ligands |
FR2794742A1 (fr) * | 1999-06-11 | 2000-12-15 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
Cited By (275)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7323475B2 (en) | 2003-06-06 | 2008-01-29 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US7629357B2 (en) | 2003-06-06 | 2009-12-08 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of user thereof |
US8916585B2 (en) | 2003-06-06 | 2014-12-23 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US11229637B2 (en) | 2003-06-06 | 2022-01-25 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US10646482B2 (en) | 2003-06-06 | 2020-05-12 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US7863292B2 (en) | 2003-06-06 | 2011-01-04 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US8765956B2 (en) | 2003-06-06 | 2014-07-01 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US8278325B2 (en) | 2003-06-06 | 2012-10-02 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US8017625B2 (en) | 2003-06-06 | 2011-09-13 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US9339527B2 (en) | 2003-06-06 | 2016-05-17 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US10092558B2 (en) | 2003-06-06 | 2018-10-09 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US7276608B2 (en) | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US7884113B2 (en) | 2003-07-11 | 2011-02-08 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US8119808B2 (en) | 2003-07-11 | 2012-02-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
EP2256106A1 (de) | 2003-07-22 | 2010-12-01 | Astex Therapeutics Limited | 3,4-disubstituierte 1H-Pyrazol-Verbindungen und deren Verwendung als Cyclin-abhängige Kinase (CDK) und Glycogen Synthase Kinase-3 (GSK-3) Modulatoren |
US7973069B2 (en) | 2004-07-14 | 2011-07-05 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7645881B2 (en) | 2004-07-22 | 2010-01-12 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2006077424A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2007045366A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische verbindungen mit carboxyl-isosteren gruppen und ihre verwendung zur behandlung von herz-kreislauf-erkrankungen |
US7998988B2 (en) | 2005-10-21 | 2011-08-16 | Bayer Schering Pharma Aktiengellschaft | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders |
US8168821B2 (en) | 2005-10-21 | 2012-05-01 | Bayer Pharma Aktiengesellschaft | Cyclopropylacetic acid derivatives and use thereof |
US8183271B2 (en) | 2005-10-21 | 2012-05-22 | Bayer Intellectual Property Gmbh | Tetrazole derivatives and their use for the treatment of cardiovascular diseases |
US8173704B2 (en) | 2005-10-21 | 2012-05-08 | Bayer Pharma Aktiengesellschaft | Difluorophenol derivatives and their use |
US8609727B2 (en) | 2005-10-21 | 2013-12-17 | Bayer Intellectual Property Gmbh | Dicarboxylic acid derivatives and their use |
US8759373B2 (en) | 2006-01-27 | 2014-06-24 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
US7928120B2 (en) | 2006-01-27 | 2011-04-19 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
US9174976B2 (en) | 2006-01-27 | 2015-11-03 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
US7696223B2 (en) | 2006-04-04 | 2010-04-13 | Fibrogen, Inc. | Pyrrolo- and Thiazolo-pyridine compounds, and methods of use thereof |
WO2007134862A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Ag | Substituierte arylimidaz0l0ne und -triaz0l0ne als inhibitoren der vasopressin-rezeptoren |
US8404723B2 (en) | 2006-09-22 | 2013-03-26 | Bayer Intellectual Property Gmbh | 3-cyano 5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases |
DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
DE102007015034A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
US7985876B2 (en) | 2007-03-29 | 2011-07-26 | Bayer Schering Pharma Aktiengesellschaft | Substituted dibenzoic acid derivatives and use thereof |
US8217063B2 (en) | 2007-03-29 | 2012-07-10 | Bayer Intellectual Property Gmbh | Lactam-substituted dicarboxylic acids and use thereof |
DE102007019690A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102007019691A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
DE102007027799A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
DE102007027800A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
US8309596B2 (en) | 2007-06-28 | 2012-11-13 | Novartis Ag | Kallikrein 7 modulators |
DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
DE102007051762A1 (de) | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
DE102007054786A1 (de) | 2007-11-16 | 2009-05-20 | Bayer Healthcare Ag | Trisubstituierte Furopyrimidine und ihre Verwendung |
EP2556831A1 (de) | 2007-12-20 | 2013-02-13 | Bayer Intellectual Property GmbH | 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidin-6-carbonitrile als Adenosin Rezeptor Liganden zur Behandlung von cardiovasculären Erkrankungen |
DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
DE102007061763A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102007061764A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102007061766A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102007061757A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung |
EP2556856A1 (de) | 2007-12-20 | 2013-02-13 | Bayer Intellectual Property GmbH | 6-Cyano-substituierte Pyrido[2,3-d]pyrimidine als Adenosin Rezeptor Liganden zur Behandlung von Kardiovakulären Erkrankungen |
DE102008007400A1 (de) | 2008-02-04 | 2009-08-06 | Bayer Healthcare Ag | Substituierte Furane und ihre Verwendung |
DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
DE102008022521A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
US8063234B2 (en) | 2008-06-25 | 2011-11-22 | Bayer Schering Pharma Aktiengesellschaft | Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof |
DE102008030207A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung |
DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
DE102008039082A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
DE102008039083A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
DE102008052013A1 (de) | 2008-10-17 | 2010-04-22 | Bayer Schering Pharma Aktiengesellschaft | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102008054205A1 (de) | 2008-10-31 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie |
US8927591B2 (en) | 2008-11-14 | 2015-01-06 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
US9149476B2 (en) | 2008-11-14 | 2015-10-06 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102008062566A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
WO2010078953A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Triazolo- und tetrazolopyrimidin-derivate als hne-inhibitoren zur behandlung von copd |
DE102009004197A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
EP2743270A1 (de) | 2009-01-29 | 2014-06-18 | Bayer Intellectual Property GmbH | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
DE102009006602A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
WO2010086101A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte dicyanopyridine und deren aminosäureester-prodrugs |
WO2010105750A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Triazol-derivate als vasopressin-rezeptor inhibitoren zur behandlung von herzinsufizienz |
DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
WO2010105770A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-acetamido-5-aryl-1,2,4-triazolone und deren verwendung |
DE102009016553A1 (de) | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
WO2010115548A1 (de) | 2009-04-06 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und sulfoximin-substituierte diaryldihydropyrimidinone und ihre verwendung |
WO2011023703A1 (de) | 2009-08-27 | 2011-03-03 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclische-substituierte 2-acetamido-5-aryl-1,2,4-triazolone und deren verwendung |
DE102009028929A1 (de) | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
US9687476B2 (en) | 2010-02-27 | 2017-06-27 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
WO2011104322A1 (de) | 2010-02-27 | 2011-09-01 | Bayer Pharma Aktiengesellschaft | Bis-arylverknüpfte aryltriazolone und ihre verwendung |
WO2011141409A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Pharma Aktiengesellschaft | Substituierte 8-alkoxy-2-aminotetralin-derivate und ihre verwendung |
DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
US8673903B2 (en) | 2010-05-14 | 2014-03-18 | Bayer Intellectual Property Gmbh | Substituted 8-alkoxy-2-aminotetralin derivatives, and use thereof |
DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
WO2011161099A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Pharma Aktiengesellschaft | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
EP2687210A1 (de) | 2010-06-25 | 2014-01-22 | Bayer Intellectual Property GmbH | Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen |
WO2012000945A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Pharma Aktiengesellschaft | Substituierte dicyanopyridine und ihre verwendung |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
WO2012007539A1 (en) | 2010-07-14 | 2012-01-19 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
WO2012028644A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Substituierte n-phenethyl-triazolonacetamide und ihre verwendung |
DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
WO2012035075A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Pharma Aktiengesellschaft | Substituierte phenylacet- und phenylpropanamide und ihre verwendung |
DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
WO2013004607A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
WO2013007563A1 (en) | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
WO2013030802A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
WO2013105058A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013105061A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013105063A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013105065A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pah and related disorders |
WO2013105066A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Salts of an ip receptor agonist |
WO2013105057A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
US9409892B2 (en) | 2012-03-09 | 2016-08-09 | Fibrogen, Inc. | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors |
WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
US9949977B2 (en) | 2012-05-09 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Bicyclically substituted uracils and the use thereof |
WO2013167495A1 (de) | 2012-05-09 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Bicyclisch-substituierte uracile und ihre verwendung |
EP3045456A1 (de) | 2012-05-09 | 2016-07-20 | Bayer Pharma Aktiengesellschaft | Bicyclisch-substituierte uracile und ihre verwendung |
US9949978B2 (en) | 2012-05-09 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Bicyclically substituted uracils and the use thereof |
US9481672B2 (en) | 2012-05-09 | 2016-11-01 | Bayer Pharma Aktiengesellschaft | Bicyclically substituted uracils and the use thereof |
US10300062B2 (en) | 2012-05-09 | 2019-05-28 | Bayer Pharma Aktiengesellschaft | Bicyclically substituted uracils and the use thereof |
US9115085B2 (en) | 2012-07-16 | 2015-08-25 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US9371288B2 (en) | 2012-07-16 | 2016-06-21 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US10272078B2 (en) | 2012-07-16 | 2019-04-30 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US10118897B2 (en) | 2012-07-16 | 2018-11-06 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US9708269B2 (en) | 2012-07-16 | 2017-07-18 | Fibrogen, Inc. | Process for making isoquinoline compounds |
US9617218B2 (en) | 2012-07-16 | 2017-04-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US9918977B2 (en) | 2012-07-16 | 2018-03-20 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US9340511B2 (en) | 2012-07-16 | 2016-05-17 | Fibrogen, Inc. | Process for making isoquinoline compounds |
WO2014012935A1 (de) | 2012-07-20 | 2014-01-23 | Bayer Pharma Aktiengesellschaft | Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung |
EA028918B1 (ru) * | 2012-07-20 | 2018-01-31 | Байер Фарма Акциенгезельшафт | Производные 5-аминотетрагидрохинолин-2-карбоновых кислот и их применение в качестве активатора растворимой гуанилатциклазы |
KR20150036084A (ko) * | 2012-07-20 | 2015-04-07 | 바이엘 파마 악티엔게젤샤프트 | 신규 5-아미노테트라히드로퀴놀린-2-카르복실산 및 그의 용도 |
US9688636B2 (en) | 2012-07-20 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
KR102137517B1 (ko) | 2012-07-20 | 2020-07-24 | 바이엘 파마 악티엔게젤샤프트 | 신규 5-아미노테트라히드로퀴놀린-2-카르복실산 및 그의 용도 |
WO2014012934A1 (de) | 2012-07-20 | 2014-01-23 | Bayer Pharma Aktiengesellschaft | Neue 5-aminotetrahydrochinolin-2-carbonsäuren und ihre verwendung |
CN104822661B (zh) * | 2012-07-20 | 2017-05-31 | 拜耳药业股份公司 | 5‑氨基四氢喹啉‑2‑羧酸及其用途 |
US10053428B2 (en) | 2012-07-20 | 2018-08-21 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
AU2013292046C1 (en) * | 2012-07-20 | 2018-03-15 | Bayer Pharma Aktiengesellschaft | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |
US9387203B2 (en) | 2012-07-20 | 2016-07-12 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
CN104822661A (zh) * | 2012-07-20 | 2015-08-05 | 拜耳药业股份公司 | 新的5-氨基四氢喹啉-2-羧酸及其用途 |
AU2013292046B2 (en) * | 2012-07-20 | 2017-12-14 | Bayer Pharma Aktiengesellschaft | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |
US9643928B2 (en) | 2013-01-24 | 2017-05-09 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
WO2014125413A1 (en) | 2013-02-13 | 2014-08-21 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
WO2014132220A1 (en) | 2013-03-01 | 2014-09-04 | Novartis Ag | Solid forms of bicyclic heterocyclic derivatives as pdgf receptor mediators |
WO2015036563A1 (de) | 2013-09-16 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten |
WO2015052065A1 (de) | 2013-10-07 | 2015-04-16 | Bayer Pharma Aktiengesellschaft | Cyclische thienouracil-carboxamide und ihre verwendung |
US9695131B2 (en) | 2013-11-08 | 2017-07-04 | Bayer Pharma Aktiengesellschaft | Substituted uracils as chymase inhibitors |
US9751843B2 (en) | 2013-11-08 | 2017-09-05 | Bayer Pharma Aktiengesellschaft | Substituted uracils and use thereof |
US9624198B2 (en) | 2013-12-19 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Substituted piperidinyltetrahydroquinolines |
US10961221B2 (en) | 2013-12-19 | 2021-03-30 | Bayer Pharma Aktiengesellschaft | Substituted piperidinyl tetrahydroquinolines |
US10323020B2 (en) | 2013-12-19 | 2019-06-18 | Bayer Pharma Aktiengesellschaft | Substituted piperidinyl tetrahydroquinolines |
EP3329920A2 (de) | 2013-12-19 | 2018-06-06 | Bayer Pharma Aktiengesellschaft | Adrenorezeptor alpha2c rezeptor antagonisten |
US9624199B2 (en) | 2013-12-19 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Substituted bipiperidinyl derivatives |
US9944621B2 (en) | 2013-12-19 | 2018-04-17 | Bayer Pharma Aktiengesellschaft | Substituted piperidinyl tetrahydroquinolines |
WO2015091415A1 (de) | 2013-12-19 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten |
WO2015150350A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen |
WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
WO2015150362A2 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung |
WO2015162456A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162459A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162461A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
US10208018B2 (en) | 2014-07-02 | 2019-02-19 | Novartis Ag | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators |
US9765067B2 (en) | 2014-07-02 | 2017-09-19 | Novartis Ag | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators |
US10550102B2 (en) | 2014-07-02 | 2020-02-04 | Novartis Ag | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators |
US9957254B2 (en) | 2014-07-02 | 2018-05-01 | Novartis Ag | Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators |
USRE49860E1 (en) | 2014-08-01 | 2024-03-05 | Bayer Pharma Aktiengesellschaft | Process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as pharmaceutical active ingredient |
US10399977B2 (en) | 2014-08-01 | 2019-09-03 | Bayer Pharma Aktiengesellschaft | Process for preparing (4S)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as a pharmaceutical active ingredient |
USRE49575E1 (en) | 2014-08-01 | 2023-07-11 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient |
US10059707B2 (en) | 2014-08-01 | 2018-08-28 | Bayer Pharma AG | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro- 1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient |
EP3660015A1 (de) | 2014-08-01 | 2020-06-03 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl- 1,4-dihydro-1,6-naphthyridin-3-carbox-amid und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff |
WO2016037954A1 (de) | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung |
US10479765B2 (en) | 2014-09-09 | 2019-11-19 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
US9771352B2 (en) | 2014-11-03 | 2017-09-26 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
WO2016113205A1 (de) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pentafluorethylpyrimidinone und ihre verwendung |
WO2016150901A1 (de) | 2015-03-26 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Heterocyclylmethyl-thienouracile als antagonisten des adenosin-a2b-rezeptors |
US10428083B2 (en) | 2015-03-26 | 2019-10-01 | Bayer Pharma Aktiengesellschaft | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor |
WO2016177660A1 (en) | 2015-05-06 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
US11166932B2 (en) | 2015-07-23 | 2021-11-09 | Bayer Pharma Aktiengesellschaft | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof |
WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
WO2017032673A1 (de) | 2015-08-21 | 2017-03-02 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff |
USRE49826E1 (en) | 2015-08-21 | 2024-02-06 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
US10336749B2 (en) | 2015-08-21 | 2019-07-02 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
WO2017081044A1 (en) | 2015-11-13 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
US10759794B2 (en) | 2015-12-10 | 2020-09-01 | Bayer Pharma Aktiengesellschaft | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders |
US10414765B2 (en) | 2015-12-10 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same |
WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
WO2017191114A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
US10472348B2 (en) | 2016-05-03 | 2019-11-12 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
US11091463B2 (en) | 2016-05-03 | 2021-08-17 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
WO2017191102A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
US10526314B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
WO2017191115A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
US10815205B2 (en) | 2016-05-03 | 2020-10-27 | Bayer Pharma Aktiengesellschaft | Amide-substituted phenyltriazole derivatives and uses thereof |
US10800746B2 (en) | 2016-05-03 | 2020-10-13 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
WO2017191105A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
WO2017191107A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted phenyltriazole derivatives and uses thereof |
US10722501B2 (en) | 2016-05-09 | 2020-07-28 | Bayer Aktiengesellschaft | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof |
WO2018011017A1 (de) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
WO2018015196A1 (de) | 2016-07-20 | 2018-01-25 | Bayer Aktiengesellschaft | Substituierte diazaheterobicyclische verbindungen und ihre verwendung |
WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
WO2018050510A1 (de) | 2016-09-14 | 2018-03-22 | Bayer Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
WO2018054846A1 (de) | 2016-09-23 | 2018-03-29 | Bayer Aktiengesellschaft | N3-cyclisch substituierte thienouracile und ihre verwendung |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018069222A1 (en) | 2016-10-14 | 2018-04-19 | Bayer Aktiengesellschaft | Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof |
US11208400B2 (en) | 2016-10-14 | 2021-12-28 | Bayer Aktiengesellschaft | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof |
WO2018073144A1 (en) | 2016-10-20 | 2018-04-26 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
EP3338764A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
WO2018114501A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
WO2018114503A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
EP3338803A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
WO2018148419A1 (en) | 2017-02-08 | 2018-08-16 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
WO2018189012A1 (de) | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituierte n-arylethyl-2-aminochinolin-4-carboxamide und ihre verwendung |
WO2018189011A1 (de) | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung |
US11098063B2 (en) | 2017-06-14 | 2021-08-24 | Bayer Aktiengesellschaft | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders |
WO2018228909A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof as task-1 and task-3 inhibitors |
WO2018228907A1 (de) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
US11426412B2 (en) | 2017-10-18 | 2022-08-30 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
WO2019081306A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081302A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081299A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | AMINE SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081292A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
US11173151B2 (en) | 2017-10-24 | 2021-11-16 | Bayer Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
US11149023B2 (en) | 2017-10-24 | 2021-10-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
WO2019081303A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081307A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
US11331314B2 (en) | 2017-10-24 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Amine substituted triazole derivatives and uses thereof |
US11298367B2 (en) | 2017-10-24 | 2022-04-12 | Bayer Aktiengesellschaft | Prodrugs of substituted triazole derivatives and uses thereof |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
US11230540B2 (en) | 2017-10-24 | 2022-01-25 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
WO2019091847A1 (de) | 2017-11-07 | 2019-05-16 | Bayer Aktiengesellschaft | Substituierte 2,4-dihydro-3h-1,2,4-triazol-3-one und ihre verwendung |
US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
EP3498298A1 (de) | 2017-12-15 | 2019-06-19 | Bayer AG | Verwendung von sgc-stimulatoren und sgc-aktivatoren alleine oder in kombination mit pde5-inhibitoren zur behandlung von knochenerkrankungen einschliesslich osteogenesis imperfecta (oi) |
US11529341B2 (en) | 2018-03-13 | 2022-12-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
EP3553081A1 (de) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Natriuretische peptidgepfropfte antikörper im vorhof |
WO2019197470A1 (en) | 2018-04-12 | 2019-10-17 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
EP3553079A1 (de) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Mit natriuretischem peptid vom c-typ gepfropfte antikörper |
WO2019197477A1 (en) | 2018-04-12 | 2019-10-17 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
WO2019197475A1 (en) | 2018-04-12 | 2019-10-17 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
EP3553082A1 (de) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Natriuretische peptidgepfropfte antikörper im gehirn |
WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
WO2019219672A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
WO2019219517A1 (en) | 2018-05-17 | 2019-11-21 | Bayer Aktiengesellschaft | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
WO2019223629A1 (zh) | 2018-05-22 | 2019-11-28 | 广东东阳光药业有限公司 | 苯基取代的二氢萘啶类化合物及其用途 |
EP3574905A1 (de) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Verfahren zum identifizieren einer untergruppe von patienten mit dcssc, die von einer behandlung mit sgc-stimulatoren und sgc-aktivatoren in einem höheren grad als eine kontrollgruppe profitiert |
WO2020109109A1 (de) | 2018-11-27 | 2020-06-04 | Bayer Aktiengesellschaft | Verfahren zur herstellung von pharmazeutischen darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
WO2020165010A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2020165031A1 (de) | 2019-02-15 | 2020-08-20 | Bayer Aktiengesellschaft | Substituierte isochinolin-piperidinylmethanon-derivate |
WO2021078135A1 (zh) | 2019-10-25 | 2021-04-29 | 广东东阳光药业有限公司 | 吡咯酰胺类化合物及其用途 |
WO2021089683A1 (en) | 2019-11-06 | 2021-05-14 | Bayer Aktiengesellschaft | Inhibitors of adrenoreceptor adrac2 |
WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021167458A1 (en) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
WO2021172982A1 (en) | 2020-02-26 | 2021-09-02 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
WO2022122910A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
EP4011873A1 (de) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituierte pyrazolo-piperidin-carbonsäuren |
EP4011874A1 (de) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituierte pyrazolo-piperidin-carbonsäuren |
WO2022122917A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
WO2022122913A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
WO2022122916A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
WO2022122914A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
CN113563250A (zh) * | 2021-07-28 | 2021-10-29 | 南华大学 | 一种苯甲酸色胺衍生物及其制备与应用 |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Also Published As
Publication number | Publication date |
---|---|
US20040082798A1 (en) | 2004-04-29 |
WO2002070510A3 (de) | 2003-01-30 |
CA2439756A1 (en) | 2002-09-12 |
CA2439756C (en) | 2011-01-11 |
JP2004529111A (ja) | 2004-09-24 |
JP4535679B2 (ja) | 2010-09-01 |
AU2002234645A1 (en) | 2002-09-19 |
US20070179139A1 (en) | 2007-08-02 |
EP1368335A2 (de) | 2003-12-10 |
DE10110750A1 (de) | 2002-09-12 |
US7705043B2 (en) | 2010-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002070510A2 (de) | Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften | |
EP1368300A1 (de) | Substituierte aminodicarbonsäurederivate | |
EP1216225B1 (de) | Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften | |
EP1216223B1 (de) | Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften | |
EP1368302B1 (de) | Neuartige aminodicarbonsäurederivate | |
WO2001019776A2 (de) | Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften | |
DE19943639A1 (de) | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften | |
EP1368303B1 (de) | Halogensubstituierte aminodicarbonsäurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen | |
EP1368301B1 (de) | Seitenkettenhalogenierte aminodicarbonsaurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen | |
EP0358118A1 (de) | Phenylamide - Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2439756 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002701292 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002569830 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002701292 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10469817 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |